VERAXA Biotech AG (NASDAQ: VRXA) has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase, marking a significant milestone in the company's oncology pipeline. The program, which is not based on VERAXA's BiTAC platform but utilizes its proprietary antibody engineering, linker, and conjugation technologies, is now entering the next stage of development. This follows the successful completion of the discovery phase conducted in collaboration with OmniAb Inc., a partnership that began in May 2025 (https://nnw.fm/nIprz).
The advancement of VXA-222 underscores VERAXA's commitment to developing next-generation cancer therapies. The company will now focus on engineering the final bispecific ADC candidate by combining the antibody binders identified through the OmniAb collaboration with its own proprietary technologies. This approach is designed to create a more potent and targeted therapy for difficult-to-treat cancers.
In parallel, VERAXA has expanded its intellectual property portfolio, filing its first BiTAC-related patent applications alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, providing a strong foundation for its future innovations.
This dual progress—advancing a key pipeline candidate and strengthening its IP position—positions VERAXA as a growing player in the biotechnology sector. The company is building a diversified oncology pipeline that includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats, all aimed at addressing challenging cancers.
For business and technology leaders, this news highlights the importance of strategic collaborations and robust IP strategies in the competitive biotech landscape. VERAXA's ability to leverage external partnerships like OmniAb while maintaining proprietary technologies demonstrates a model for innovation in precision medicine. The extended patent protection through 2047 ensures long-term exclusivity for its breakthroughs, potentially impacting market dynamics in oncology therapeutics.
The company's progress also reflects broader trends in the pharmaceutical industry, where bispecific antibodies and ADCs are gaining traction due to their ability to target tumors more selectively while minimizing side effects. As VERAXA moves VXA-222 into preclinical validation, the industry will be watching for data that could signal a new class of cancer treatments.
Investors and stakeholders can find more information about VERAXA's developments in the company's newsroom at https://nnw.fm/VRXA.
